{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in the tumor microenvironment.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The interferon response was measured as a normalized score; absolute cytokine concentrations were not reported."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination increases the diversity and quantity of tumor-associated peptides presented on MHC-I molecules.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        }
      ],
      "caveat": "The immunopeptidomics analysis was performed on bulk tumor tissue; single-cell resolution of peptide presentation was not achieved."
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 expression increases following mRNA vaccination, making tumors more susceptible to PD-L1 blockade therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "PD-L1 expression was measured by fold-change; absolute expression levels and spatial distribution were not detailed."
    },
    {
      "claim_id": "C04",
      "claim": "Patients who received SARS-CoV-2 mRNA vaccination showed improved survival outcomes when undergoing immune checkpoint inhibitor treatment.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Human retrospective metastatic cohort: 130 patients total | Human vaccinated subgroup: 43 patients | Human unvaccinated subgroup: 87 patients",
          "line_ref": "L21-L23"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; vaccination timing relative to ICI initiation varied across patients."
    },
    {
      "claim_id": "C05",
      "claim": "The combination of intratumoral mRNA vaccination and anti-PD-L1 therapy produces superior tumor control compared to either treatment alone.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.",
          "line_ref": "L19"
        },
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        }
      ],
      "caveat": "Tumor control was assessed in murine models; human translation requires prospective randomized trials."
    }
  ]
}